SH
SHINIL PHARMACEUTICAL CO., LTD.
012790 | KO
Overview
Corporate Details
- ISIN(s):
- KR7012790002
- LEI:
- Country:
- South Korea
- Address:
- 충북 충주시 앙성면 본평리 산 5-1, 충주시
- Website:
- https://shinilpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 841.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 876.9 KB | ||
| 2025-03-24 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.2 KB | ||
| 2025-03-14 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 17.2 KB | ||
| 2025-03-14 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 1.0 MB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.8 KB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 87.0 KB | ||
| 2025-03-04 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 9.3 KB | ||
| 2024-12-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2024-12-16 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.6 KB | ||
| 2024-11-14 00:00 |
Quarterly Report
분기보고서 (2024.09)
|
Korean | 740.8 KB | ||
| 2024-08-09 00:00 |
Interim / Quarterly Report
반기보고서 (2024.06)
|
Korean | 738.9 KB | ||
| 2024-06-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 20.9 KB | ||
| 2024-05-16 00:00 |
Quarterly Report
분기보고서 (2024.03)
|
Korean | 788.8 KB |
Automate Your Workflow. Get a real-time feed of all SHINIL PHARMACEUTICAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SHINIL PHARMACEUTICAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHINIL PHARMACEUTICAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
United States of America
NVCT
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
Japan
4565
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Norway
NYKD
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
Switzerland
OBSN
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
United States of America
OCGN
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL
United States of America
OCUL
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
Switzerland
OCS
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
Sweden
ODI
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
United States of America
OKYO
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
United States of America
OLMA